Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Latest Review Papers in Molecular Neurobiology 2025
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Latest Review Papers in Molecular Neurobiology 2025

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 1899

Special Issue Editor

Dr. Hyo Eun Moon

E-Mail Website
Guest Editor
Department of Neurosurgery, Seoul National University Hospital, Seoul 03080, Republic of Korea
Interests: brain cancer; therapeutics; translational research

Special Issue Information

Dear Colleagues,

This Special Issue aims to collect high-quality review papers in all fields of neurobiology. Understanding the brain remains one of the great intellectual challenges for science, and it requires the integration of approaches from many disciplines. Neurobiology aims to study how the nervous system works, how it is built, how it operates on the cellular and system levels, how drugs affect it, and how it is damaged in neurological diseases. These are exciting times for neurobiology research, with diverse research areas spanning cellular/molecular aspects, systems, the neurobiology of disease, cognitive aspects, and computational approaches. We encourage researchers from related fields to contribute review papers that explore the latest developments in neurobiology, or to invite relevant experts and colleagues to do so. Full-length comprehensive reviews are favoured.

Dr. Hyo Eun Moon
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurobiology
  • neurochemistry
  • neurology
  • neuropathology
  • neurophysiology
  • neuropharmacology.
  • neurogenetics
  • neuro-oncology
  • aging neuroscience
  • neurotrauma
  • neurogenesis
  • neurotransmitter
  • neuroinflammation
  • neuroendocrine tumor
  • neurodegenerative diseases
  • neuroscience
  • molecular and cellular neuroscience
  • cognitive neuroscience
  • computational neuroscience

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

20 pages, 1136 KiB  
Review
Kinase-Targeted Therapies for Glioblastoma
by Maria Salbini, Alessia Formato, Maria Patrizia Mongiardi, Andrea Levi and Maria Laura Falchetti
Int. J. Mol. Sci. 2025, 26(8), 3737; https://doi.org/10.3390/ijms26083737 - 15 Apr 2025
Viewed by 117
Abstract
Protein phosphorylation and dephosphorylation are key mechanisms that regulate cellular activities. The addition or removal of phosphate groups by specific enzymes, known as kinases and phosphatases, activates or inhibits many enzymes and receptors involved in various cell signaling pathways. Dysregulated activity of these [...] Read more.
Protein phosphorylation and dephosphorylation are key mechanisms that regulate cellular activities. The addition or removal of phosphate groups by specific enzymes, known as kinases and phosphatases, activates or inhibits many enzymes and receptors involved in various cell signaling pathways. Dysregulated activity of these enzymes is associated with various diseases, predominantly cancers. Synthetic and natural single- and multiple-kinase inhibitors are currently being used as targeted therapies for different tumors, including glioblastoma. Glioblastoma IDH-wild-type is the most aggressive brain tumor in adults, with a median overall survival of 15 months. The great majority of glioblastoma patients present mutations in receptor tyrosine kinase (RTK) signaling pathways responsible for tumor initiation and/or progression. Despite this, the multi-kinase inhibitor regorafenib has only recently been approved for glioblastoma patients in some countries. In this review, we analyze the history of kinase inhibitor drugs in glioblastoma therapy. Full article
(This article belongs to the Special Issue Latest Review Papers in Molecular Neurobiology 2025)
►▼ Show Figures

Graphical abstract

18 pages, 1206 KiB  
Review
Reactive Oxygen Species as a Common Pathological Link Between Alcohol Use Disorder and Alzheimer’s Disease with Therapeutic Implications
by Hyein Song, Jiyong Lee, Yeeun Lee, Seungju Kim and Shinwoo Kang
Int. J. Mol. Sci. 2025, 26(7), 3272; https://doi.org/10.3390/ijms26073272 - 1 Apr 2025
Viewed by 406
Abstract
Chronic alcohol consumption leads to excessive production of reactive oxygen species (ROS), driving oxidative stress that contributes to both alcohol use disorder (AUD) and Alzheimer’s disease (AD). This review explores how ROS-mediated mitochondrial dysfunction and neuroinflammation serve as shared pathological mechanisms linking these [...] Read more.
Chronic alcohol consumption leads to excessive production of reactive oxygen species (ROS), driving oxidative stress that contributes to both alcohol use disorder (AUD) and Alzheimer’s disease (AD). This review explores how ROS-mediated mitochondrial dysfunction and neuroinflammation serve as shared pathological mechanisms linking these conditions. We highlight the role of alcohol-induced oxidative damage in exacerbating neurodegeneration and compare ROS-related pathways in AUD and AD. Finally, we discuss emerging therapeutic strategies, including mitochondrial antioxidants and inflammasome inhibitors, that target oxidative stress to mitigate neurodegeneration. Understanding these overlapping mechanisms may provide new insights for preventing and treating ROS-driven neurodegenerative disorders. Full article
(This article belongs to the Special Issue Latest Review Papers in Molecular Neurobiology 2025)
►▼ Show Figures

Figure 1

22 pages, 1396 KiB  
Review
Cell-Free Nucleic Acids for Early Diagnosis of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
by Xiaodan Zhang, Yuee Cai, Brian Hon Man Sit, Rain Xiaoyu Jian, Yasine Malki, Yilin Zhang, Christopher Chi Yat Ong, Qianyun Li, Rex Pui Kin Lam and Timothy Hudson Rainer
Int. J. Mol. Sci. 2025, 26(4), 1530; https://doi.org/10.3390/ijms26041530 - 12 Feb 2025
Viewed by 815
Abstract
Rapid identification of acute ischemic stroke (AIS) is challenging in both pre-hospital and hospital settings. We aimed to identify the most promising cell-free nucleic acids (cfNAs) as diagnostic biomarkers for IS within 72 h from symptom onset. We searched PubMed, Web of Science, [...] Read more.
Rapid identification of acute ischemic stroke (AIS) is challenging in both pre-hospital and hospital settings. We aimed to identify the most promising cell-free nucleic acids (cfNAs) as diagnostic biomarkers for IS within 72 h from symptom onset. We searched PubMed, Web of Science, EMBASE, and Cochrane Library for published articles that evaluated blood cfNAs in the early diagnosis of AIS until 10 May 2023. The diagnostic performances of individual cfNAs were pooled by random-effects meta-analysis based on the fold change of biomarkers’ level between AIS and non-AIS patients. Of 2955 records, 66 articles reporting 143 different cfNAs met the inclusion criteria. The median sample size was 110, and 21.4% of the studies performed validation. Among selected high-quality studies, miR-106b-5p, miR-124, miR-155, lncRNA H19, and cfDNA showed good diagnostic performance. Data from four studies on cfDNA involving 355 AIS patients and 97 controls were pooled in the meta-analysis, which showed a significant fold change between AIS and controls (pooled ratio 1.48, 95% confidence interval 1.23–1.79, p < 0.001). This review highlights that cfDNA, miR-106b-5p, miR-124, miR-155, and lncRNA H19 are the most promising biomarkers for AIS diagnosis, and further research is needed for verification. Full article
(This article belongs to the Special Issue Latest Review Papers in Molecular Neurobiology 2025)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop